Merck's ifinatamab deruxtecan wins FDA Breakthrough Therapy status for treating adults with extensive-stage small cell lung ...

After six days of gains, shares dropped, reflecting mixed momentum. See insights on earnings, cost-cutting, and analyst ratings.

Merck & Co., Inc. (NYSE:MRK) is included in our list of the 10 Most Undervalued Value Stocks to Buy Now. On August 12, 2025, ...

Merck’s MRK strong foothold in the oncology space is propelled by its biggest revenue driver, Keytruda. The blockbuster PD-L1 ...

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Merck ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

Below is Validea's guru fundamental report for MERCK & CO INC (MRK). Of the 22 guru strategies we follow, MRK rates highest using our P/E/Growth Investor model based on the published strategy of ...

Investors in Merck & Co Inc (Symbol: MRK) saw new options begin trading today, for the September 26th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MRK ...

Japan 1st Quarter Ended June 30 GROUP 2025 2024 Revenue Y4.72 bln Y4.46 bln Operating Profit (Y458.00 mln) (Y379.00 mln) Pretax Profit (Y313.00 mln) (Y332.00 mln) Net Profit (Y182.00 mln) (Y266.00 mln ...